Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Effect of carbamazepine on the blood levels of BI 1810631 after a single dose in healthy men

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

The investigation involves healthy male volunteers, so no disease is being treated. It examines whether the medicine carbamazepine, a drug commonly used for seizure control that can speed up the activity of certain body enzymes, influences the amount of a new experimental compound called BI 1810631 that appears in the blood. The purpose is to determine if carbamazepine changes the pharmacokinetics – that is, how the body absorbs, distributes, and clears the new drug.

Participants will first take carbamazepine tablets for several days, then receive a single dose of the experimental drug. Blood samples will be collected at several times after the dose to measure the drug level. After a short break, the same participants will receive the experimental drug alone, with another series of blood samples taken. The study compares the drug amounts with and without carbamazepine to see if the enzyme‑activating effect of carbamazepine, known as CYP3A induction, alters the blood concentration of the new medication.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline assessment

    You will attend an initial visit where health information is recorded and basic laboratory tests are performed to confirm eligibility.

    This visit marks the start of your participation in the study.

  2. Step 2

    First study period – single dose of <b>BI 1810631</b>

    You will receive one oral tablet containing 60 mg of BI 1810631 (film‑coated tablet).

    The tablet is taken once, with water, under supervision of the study staff.

    Blood samples will be collected at several time points after the dose to measure the amount of drug in your plasma.

  3. Step 3

    Second study period – multiple doses of <b>carbamazepine</b> followed by a single dose of <b>BI 1810631</b>

    You will take oral carbamazepine tablets each day for a number of days as specified by the study protocol.

    The tablets are either 600 mg or 400 mg prolonged‑release tablets (designed to release the medicine slowly over time).

    After the series of carbamazepine doses, you will receive another single oral tablet of BI 1810631 (60 mg, film‑coated).

    As in the first period, blood samples will be drawn at multiple time points after this dose to assess how the carbamazepine treatment influences the level of BI 1810631 in your blood.

  4. Step 4

    Final follow‑up

    After the last blood sample, you will have a final visit during which any remaining study procedures are completed and a safety check is performed.

    You will be thanked for your contribution and given information about the study’s completion.

Who can join the trial?

4 criteria

  • Be a male who is in good health, confirmed by the doctor through a medical history, physical exam, checks of vital signs such as blood pressure (BP) and pulse rate (PR), a heart test called a 12‑lead ECG, and routine lab tests.
  • Be between 18 and 55 years old, including the ages at the ends of the range.
  • Have a body mass index (BMI) between 18.5 and 29.9 kilograms per square meter, which is a standard measure of weight relative to height.
  • Provide a signed and dated written informed consent form, showing you understand the study and agree to take part, as required by international guidelines and local laws.

Who cannot join the trial?

5 criteria

  • If any part of the medical exam—such as blood pressure, the heart‑electric test (ECG), nerve check, or skin inspection—shows an abnormal result that the doctor thinks is important.
  • If repeated checks show a systolic blood pressure (the top number) lower than 90 mmHg or higher than 140 mmHg, a diastolic blood pressure (the bottom number) lower than 50 mmHg or higher than 90 mmHg, or a pulse rate (heart beats per minute) lower than 50 bpm or higher than 90 bpm.
  • If any laboratory value (such as blood or urine test results) is outside the normal range and the doctor believes it matters for the study.
  • If there is any other health condition (concomitant disease) that the doctor assesses as important for the study.
  • If any additional exclusion reasons apply that are not listed here.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • BI 1810631

    is an experimental medicine being studied for the first time in people. In this trial participants take a single oral tablet of BI 1810631, and researchers measure how the drug is absorbed, distributed, and cleared from the body. The purpose is to understand its behavior in the bloodstream when no other medicines are affecting it.

  • carbamazepine

    is a medication that is known to increase the activity of an enzyme called CYP3A, which helps the body process many drugs. In this study, healthy volunteers take carbamazepine repeatedly over several days. The researchers then give a single dose of BI 1810631 to see how carbamazepine changes the way BI 1810631 is handled by the body. This helps determine whether carbamazepine could affect the effectiveness or safety of BI 1810631 when both are used together.

What is already known about the treatment

  • BI 1810631

    This drug is taken by mouth as a film‑coated tablet, with a single 60 mg dose used in the study. It is currently an investigational medicine that has not been approved for any disease and is only described in early clinical research. The trial is exploring how it behaves in the body when another drug, carbamazepine, is taken at the same time; its exact therapeutic purpose is still being defined. BI 1810631 is a small‑molecule compound that is thought to be processed by the liver enzyme CYP3A, and it is classified as an experimental oral agent.

  • Carbamazepine

    Carbamazepine is taken by mouth as a prolonged‑release tablet, usually in doses of 400 mg or 600 mg once daily. It is an approved medication that has been used for many years to treat epilepsy, certain types of nerve pain, and bipolar disorder. The drug works by calming over‑active nerve cells, mainly by blocking sodium channels that help generate electrical signals. Carbamazepine belongs to the class of anticonvulsant (anti‑seizure) medicines and is known to strongly increase the activity of the liver enzyme CYP3A.

Investigated diseases

Neoplasm - A neoplasm is an abnormal collection of cells that grows in an uncontrolled way, forming a mass. It may be benign, staying localized, or malignant, where cells can invade nearby tissue. Malignant neoplasms can also spread to distant parts of the body through the bloodstream or lymphatic system. The rate of growth varies; some expand slowly over years, while others enlarge rapidly. As the mass enlarges, it can compress or replace normal structures, affecting organ function.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2022-503046-50-00Protocol code1479-0011Estimated enrolment16 patientsSponsorBoehringer Ingelheim International GmbH

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.